MilliporeSigma Expands Distribution Agreement with Roche
Billerica, Massachusetts, December 1, 2016—MilliporeSigma today announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction...
- MilliporeSigma to be the exclusive supplier of novel enzymes for polymerase chain reaction (PCR) and quantitative real-time PCR, for all countries except the U.S., Brazil and Japan
- Exclusive global distributor for Roche’s biochemical reagents portfolio since 2015
Billerica, Massachusetts, December 1, 2016—MilliporeSigma today announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015.
The addition of the Kapa portfolio strengthens MilliporeSigma’s existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR in the industry today.
“The alliance extension with Roche will offer our customers greater access to novel products via our world-class distribution channel,” said Udit Batra, Member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. “These enzymes represent a significant advantage over commercially available DNA polymerases and thus offer the potential for entirely new PCR applications.”
Under the terms of the agreement, MilliporeSigma will employ its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to present and distribute Kapa PCR and quantitative PCR reagents and kits. The distribution agreement includes all geographies except the U.S., Japan and Brazil. Financial details were not disclosed.
Roche inked the global exclusive distribution agreement for its Biochemical Reagents portfolio with Sigma-Aldrich in July 2015. Following the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany in the same year, this agreement became an important part of the life science business of Merck KGaA, Darmstadt, Germany, driving growth in its life science business and offering premier brand tools for genomics, proteomics and cell analysis.
The novel PCR enzymes offered under the expanded distribution agreement have improved tolerance to common PCR inhibitors, increased speed and specific activity, and higher fidelity. These characteristics enable higher quality results and improved workflows.i
Transition of Kapa’s PCR and qPCR portfolios to MilliporeSigma is expected to be completed by January 1, 2017. In the interim, these products will continue to be available through existing Kapa channels. For more information, visit www.sigma-aldrich.com/kapa.
i Data on file
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany Highlights Commitment to Improving Cancer Outcomes ...
Merck KGaA, Darmstadt, Germany, announced 43 abstracts covering modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.